CBUS · Cibus, Inc.
Substantial doubt about the company's ability to continue as a going concern.
“These factors raise substantial doubt about the Company's ability to continue as a going concern within one year from the issuance of these condensed consolidated financial statements.”View the 10-Q filed Aug 13, 2026
Price & Indicators
Raw chart and full-history price indicators begin at the captured split on Jun 1, 2023; bars on opposite sides are not compared.
Up next
AI Brief
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Annual net cash usage run-rate exiting 2026 | $35M | FY2026 exit run-rate | — |
| Net cash used in operating activities | $20.9M | six months ended June 30, 2026 | — |
| Patents and patent applications | 500 | Q2 2026 | — |
| Quarterly net cash usage decline (sequentially) | 19% | Q2 2026 | — |
| Quarterly net cash usage decline (year over year) | 31% | Q2 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CBUS
this stock
Cibus, Inc.
|
$135.28M | +1.7% | -14.6% | — | 4.7% |
|
ONC
BeOne Medicines Ltd.
|
$530.72B | +14.4% | +22179.2% | 816.0 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.25B | +11.6% | +46.2% | 30.6 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$82.16B | +4.1% | +20.8% | 19.8 | 3.3% |
|
ARGX
Argenx SE
|
$52.69B | +1.2% | — | — | 2.1% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
Raw-price comparisons begin at the captured split on Jun 1, 2023; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CBUS | -2.2% | -1.1% | -45.9% | -8.3% | +1.7% |
| SPY | +0.4% | +4.5% | +13.8% | +3.9% | +13.9% |
| vs SPY | -2.6% | -5.6% | -59.6% | -12.2% | -12.1% |